Neogen Co. (NASDAQ:NEOG - Free Report) - Investment analysts at Zacks Research raised their Q3 2025 earnings estimates for shares of Neogen in a research report issued on Monday, March 3rd. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.12 for the quarter, up from their previous estimate of $0.11. The consensus estimate for Neogen's current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen's FY2025 earnings at $0.39 EPS.
Neogen (NASDAQ:NEOG - Get Free Report) last released its quarterly earnings data on Friday, January 10th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.01) by $0.12. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The company had revenue of $231.30 million during the quarter, compared to analysts' expectations of $227.16 million. During the same period last year, the firm posted $0.11 earnings per share. The business's revenue was up .7% on a year-over-year basis.
Several other analysts also recently commented on the stock. Piper Sandler reaffirmed a "neutral" rating and set a $13.00 target price (down previously from $16.50) on shares of Neogen in a report on Tuesday, January 21st. Guggenheim assumed coverage on Neogen in a report on Thursday, December 19th. They set a "buy" rating and a $15.00 price objective for the company.
Read Our Latest Stock Report on NEOG
Neogen Stock Performance
Shares of NASDAQ:NEOG traded down $0.42 on Thursday, hitting $9.98. The company had a trading volume of 3,656,964 shares, compared to its average volume of 1,976,562. The stock has a market cap of $2.17 billion, a price-to-earnings ratio of -4.56 and a beta of 1.27. The stock has a 50 day moving average price of $11.05 and a 200 day moving average price of $13.44. Neogen has a 1-year low of $9.01 and a 1-year high of $18.58. The company has a current ratio of 3.77, a quick ratio of 2.46 and a debt-to-equity ratio of 0.33.
Insider Buying and Selling
In related news, CFO David H. Naemura bought 14,800 shares of the company's stock in a transaction dated Thursday, January 16th. The stock was purchased at an average price of $11.11 per share, with a total value of $164,428.00. Following the completion of the acquisition, the chief financial officer now owns 61,434 shares of the company's stock, valued at $682,531.74. The trade was a 31.74 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John Edward Adent purchased 23,035 shares of Neogen stock in a transaction dated Thursday, January 16th. The stock was bought at an average price of $11.03 per share, for a total transaction of $254,076.05. Following the completion of the purchase, the chief executive officer now owns 269,164 shares in the company, valued at $2,968,878.92. This represents a 9.36 % increase in their position. The disclosure for this purchase can be found here. 1.13% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Neogen
Several institutional investors and hedge funds have recently added to or reduced their stakes in NEOG. Allspring Global Investments Holdings LLC lifted its stake in shares of Neogen by 142.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company's stock valued at $33,000 after acquiring an additional 1,165 shares during the last quarter. International Assets Investment Management LLC raised its position in Neogen by 1,581.0% in the third quarter. International Assets Investment Management LLC now owns 11,666 shares of the company's stock valued at $196,000 after purchasing an additional 10,972 shares during the last quarter. State of Alaska Department of Revenue boosted its stake in shares of Neogen by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 22,810 shares of the company's stock valued at $383,000 after purchasing an additional 1,550 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Neogen by 12.4% during the third quarter. Nisa Investment Advisors LLC now owns 28,258 shares of the company's stock valued at $475,000 after purchasing an additional 3,123 shares in the last quarter. Finally, New York State Teachers Retirement System grew its holdings in shares of Neogen by 2.5% during the third quarter. New York State Teachers Retirement System now owns 140,005 shares of the company's stock worth $2,353,000 after purchasing an additional 3,430 shares during the last quarter. Institutional investors own 96.73% of the company's stock.
About Neogen
(
Get Free Report)
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.
Featured Articles

Before you consider Neogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neogen wasn't on the list.
While Neogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.